Cargando…

Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme

E1 enzymes activate ubiquitin (Ub) and ubiquitin-like modifiers (Ubls) in the first step of Ub/Ubl conjugation cascades and represent potential targets for therapeutic intervention in cancer and other life-threatening diseases. Here, we report the crystal structure of the E1 enzyme for the Ubl SUMO...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Zongyang, Yuan, Lingmin, Atkison, James H., Williams, Katelyn M., Vega, Ramir, Sessions, E. Hampton, Divlianska, Daniela B., Davies, Christopher, Chen, Yuan, Olsen, Shaun K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279746/
https://www.ncbi.nlm.nih.gov/pubmed/30514846
http://dx.doi.org/10.1038/s41467-018-07015-1
_version_ 1783378528864043008
author Lv, Zongyang
Yuan, Lingmin
Atkison, James H.
Williams, Katelyn M.
Vega, Ramir
Sessions, E. Hampton
Divlianska, Daniela B.
Davies, Christopher
Chen, Yuan
Olsen, Shaun K.
author_facet Lv, Zongyang
Yuan, Lingmin
Atkison, James H.
Williams, Katelyn M.
Vega, Ramir
Sessions, E. Hampton
Divlianska, Daniela B.
Davies, Christopher
Chen, Yuan
Olsen, Shaun K.
author_sort Lv, Zongyang
collection PubMed
description E1 enzymes activate ubiquitin (Ub) and ubiquitin-like modifiers (Ubls) in the first step of Ub/Ubl conjugation cascades and represent potential targets for therapeutic intervention in cancer and other life-threatening diseases. Here, we report the crystal structure of the E1 enzyme for the Ubl SUMO in complex with a recently discovered and highly specific covalent allosteric inhibitor (COH000). The structure reveals that COH000 targets a cryptic pocket distinct from the active site that is completely buried in all previous SUMO E1 structures and that COH000 binding to SUMO E1 is accompanied by a network of structural changes that altogether lock the enzyme in a previously unobserved inactive conformation. These structural changes include disassembly of the active site and a 180° rotation of the catalytic cysteine-containing SCCH domain, relative to conformational snapshots of SUMO E1 poised to catalyze adenylation. Altogether, our study provides a molecular basis for the inhibitory mechanism of COH000 and its SUMO E1 specificity, and also establishes a framework for potential development of molecules targeting E1 enzymes for other Ubls at a cryptic allosteric site.
format Online
Article
Text
id pubmed-6279746
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62797462018-12-06 Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme Lv, Zongyang Yuan, Lingmin Atkison, James H. Williams, Katelyn M. Vega, Ramir Sessions, E. Hampton Divlianska, Daniela B. Davies, Christopher Chen, Yuan Olsen, Shaun K. Nat Commun Article E1 enzymes activate ubiquitin (Ub) and ubiquitin-like modifiers (Ubls) in the first step of Ub/Ubl conjugation cascades and represent potential targets for therapeutic intervention in cancer and other life-threatening diseases. Here, we report the crystal structure of the E1 enzyme for the Ubl SUMO in complex with a recently discovered and highly specific covalent allosteric inhibitor (COH000). The structure reveals that COH000 targets a cryptic pocket distinct from the active site that is completely buried in all previous SUMO E1 structures and that COH000 binding to SUMO E1 is accompanied by a network of structural changes that altogether lock the enzyme in a previously unobserved inactive conformation. These structural changes include disassembly of the active site and a 180° rotation of the catalytic cysteine-containing SCCH domain, relative to conformational snapshots of SUMO E1 poised to catalyze adenylation. Altogether, our study provides a molecular basis for the inhibitory mechanism of COH000 and its SUMO E1 specificity, and also establishes a framework for potential development of molecules targeting E1 enzymes for other Ubls at a cryptic allosteric site. Nature Publishing Group UK 2018-12-04 /pmc/articles/PMC6279746/ /pubmed/30514846 http://dx.doi.org/10.1038/s41467-018-07015-1 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lv, Zongyang
Yuan, Lingmin
Atkison, James H.
Williams, Katelyn M.
Vega, Ramir
Sessions, E. Hampton
Divlianska, Daniela B.
Davies, Christopher
Chen, Yuan
Olsen, Shaun K.
Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme
title Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme
title_full Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme
title_fullStr Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme
title_full_unstemmed Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme
title_short Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme
title_sort molecular mechanism of a covalent allosteric inhibitor of sumo e1 activating enzyme
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279746/
https://www.ncbi.nlm.nih.gov/pubmed/30514846
http://dx.doi.org/10.1038/s41467-018-07015-1
work_keys_str_mv AT lvzongyang molecularmechanismofacovalentallostericinhibitorofsumoe1activatingenzyme
AT yuanlingmin molecularmechanismofacovalentallostericinhibitorofsumoe1activatingenzyme
AT atkisonjamesh molecularmechanismofacovalentallostericinhibitorofsumoe1activatingenzyme
AT williamskatelynm molecularmechanismofacovalentallostericinhibitorofsumoe1activatingenzyme
AT vegaramir molecularmechanismofacovalentallostericinhibitorofsumoe1activatingenzyme
AT sessionsehampton molecularmechanismofacovalentallostericinhibitorofsumoe1activatingenzyme
AT divlianskadanielab molecularmechanismofacovalentallostericinhibitorofsumoe1activatingenzyme
AT davieschristopher molecularmechanismofacovalentallostericinhibitorofsumoe1activatingenzyme
AT chenyuan molecularmechanismofacovalentallostericinhibitorofsumoe1activatingenzyme
AT olsenshaunk molecularmechanismofacovalentallostericinhibitorofsumoe1activatingenzyme